[1]章云云.美洛西林联合阿奇霉素治疗小儿肺炎链球菌肺炎的临床效果[J].医学信息,2023,36(13):131-133,137.[doi:10.3969/j.issn.1006-1959.2023.13.027]
　ZHANG Yun-yun.Clinical Effect of Mezlocillin Combined with Azithromycin in the Treatment of Children with Streptococcus Pneumoniae Pneumonia[J].Journal of Medical Information,2023,36(13):131-133,137.[doi:10.3969/j.issn.1006-1959.2023.13.027]
点击复制

美洛西林联合阿奇霉素治疗小儿肺炎链球菌肺炎的临床效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年13期
页码:
131-133,137
栏目:
论著
出版日期:
2023-07-01

文章信息/Info

Title:
Clinical Effect of Mezlocillin Combined with Azithromycin in the Treatment of Children with Streptococcus Pneumoniae Pneumonia
文章编号:
1006-1959（2023）13-0131-04
作者:
章云云
（金溪县人民医院儿科，江西 金溪 344800）
Author(s):
ZHANG Yun-yun
(Department of Pediatrics, Jinxi County People’s Hospital, Jinxi 344800, Jiangxi, China)
关键词:
小儿肺炎链球菌肺炎; 美洛西林; 阿奇霉素; 肺功能
Keywords:
Streptococcus pneumoniae pneumonia in children; Mezlocillin; Azithromycin; Lung function
分类号:
R725.6
DOI:
10.3969/j.issn.1006-1959.2023.13.027
文献标志码:
A
摘要:
目的 研究美洛西林联合阿奇霉素治疗小儿肺炎链球菌肺炎的临床效果。方法 以2020年1月-2021年12月抚州市金溪县人民医院收治的80例小儿肺炎链球菌肺炎患儿为研究对象，按照随机数字表法分为对照组（40例）与观察组（40例）。对照组给予美洛西林治疗，观察组应用美洛西林联合阿奇霉素治疗，比较两组临床疗效、症状消失时间（退热时间、咳嗽消失时间、肺部啰音消失时间）、肺功能[用力肺活量（FVC）、第一秒末用力呼气容积（FEV1）、FEV1占预计值百分比（FEV1%）]、炎性指标[白细胞计数（WBC）、C反应蛋白（CRP）]、不良反应。结果 观察组治疗总有效率高于对照组（P＜0.05）；观察组退热时间、咳嗽消失时间、肺部啰音消失时间均短于对照组（P＜0.05）；两组治疗后FVC、FEV1、FEV1%高于治疗前，且观察组高于对照组（P＜0.05）；两组治疗后WBC、CRP指标低于治疗前，且观察组WBC、CRP指标低于对照组（P＜0.05）；观察组不良反应发生率小于对照组（P＜0.05）。结论 美洛西林联合阿奇霉素治疗小儿肺炎链球菌肺炎效果确切，可加速症状消退，改善患儿肺功能，下调炎性指标，减少不良反应。
Abstract:
Objective To study the clinical effect of mezlocillin combined with azithromycin in the treatment of children with Streptococcus pneumoniae pneumonia.Methods A total of 80 children with Streptococcus pneumoniae pneumonia admitted to Jinxi County People’s Hospital of Fuzhou City from January 2020 to December 2021 were selected as the research objects. According to the random number table method, they were divided into control group (40 children) and observation group (40 children). The control group was treated with mezlocillin, and the observation group was treated with mezlocillin combined with azithromycin. The clinical efficacy, symptom disappearance time (antifebrile time, cough disappearance time, lung rale disappearance time), lung function [forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1 percentage of predicted value (FEV1%)], inflammatory indicators [white blood cell count (WBC), C-reactive protein (CRP)] and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group (P<0.05). The antipyretic time, cough disappearance time and lung rale disappearance time in the observation group were shorter than those in the control group (P<0.05). After treatment, FVC, FEV1 and FEV1% in the two groups were higher than those before treatment, and those in the observation group were higher than the control group (P<0.05). The WBC and CRP indexes of the two groups after treatment were lower than those before treatment, and the WBC and CRP indexes of the observation group were lower than those of the control group (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05).Conclusion Mezlocillin combined with azithromycin is effective in the treatment of children with Streptococcus pneumoniae pneumonia, which can accelerate the regression of symptoms, improve the lung function of children, down-regulate inflammatory indicators and reduce adverse reactions.

参考文献/References:

[1]徐忠,张瑾,韩美林,等.苏州地区儿童侵袭性肺炎链球菌病80例血清学分型和临床特征[J].中国小儿急救医学,2018,25(12):933-938.[2]Shakhnovich EA,King SJ,Weiser JN.Neuraminidase Expressed by Streptococcus pneumoniae Desialylates the Lipopolysaccharide of Neisseria meningitidis and Haemophilus influenzae: a Paradigm for Interbacterial Competition among Pathogens of the Human Respiratory Tract[J].Infection and Immunity,2019,12(12):7161-7165.[3]詹平,吕燕清,刘发英,等.红霉素和阿奇霉素对肺炎支原体感染儿童血清应激指标水平以及肺功能的影响[J].临床肺科杂志,2020,25(5):707-710.[4]周鸿良,朱彤,沈佩芳.小儿肺炎患者院感病原菌检测、耐药性及其防治措施[J].中国卫生检验杂志,2019,29(6):737-739.[5]郭亚红,范华杰,李清,等.奈替米星联合美洛西林对急性获得性肺炎患者肺功能及Th1/Th2细胞因子的影响[J].湖南师范大学学报(医学版),2019,16(6):96-98.[6]王芳,王森,王川.小儿肺热咳喘口服液联合美洛西林钠治疗小儿肺炎的临床研究[J].现代药物与临床,2018,33(7):1664-1667.[7]花元清.阿奇霉素联合红霉素治疗小儿支原体肺炎的临床效果分析[J].中国妇幼保健,2019,34(11):2535-2536.[8]张燕.阿奇霉素联合红霉素治疗小儿支原体肺炎的临床效果评价[J].中国药物与临床,2018,18(8):1376-1377.[9]杨云,王卫中,田静,等.小儿肺炎链球菌肺炎治疗后临床效果和影像学特点[J].河北医药,2017,39(21):3261-3264.[10]Whiting JL,Cheng N,Chow AW.Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against gram-positive and gram-negative anaerobic bacteria[J].Antimicrob Agents Chemother,1987,31(9):1379-1382.[11]段永彬,歹丽红,张俊霞.金振口服液联合美洛西林治疗小儿急性支气管炎的临床研究[J].现代药物与临床,2021,36(5):1036-1039.[12]孙晓玄,黄晓英,张锦琪.阿奇霉素序贯疗法治疗小儿支原体肺炎的疗效及不良反应观察[J].贵州医药,2017,41(11):1149-1150.[13]盛江吟,李昌崇,张海邻,等.不同疗程阿奇霉素治疗儿童轻症肺炎支原体肺炎疗效比较[J].儿科药学杂志,2018,24(1):10-12.[14]李南洋,岑丽莲,赖汉瑜.儿童侵袭性肺炎链球菌病临床特征与血清型分布[J].医学动物防制,2017,33(9):1012-1013.[15]王培养,顾承萍.阿奇霉素联合布地奈德治疗小儿支原体肺炎的临床疗效分析[J].中国微生态学杂志,2017,29(5):574-576.[16]李连家,孙玉军,马海凤,等.小儿肺热咳喘口服液联合美洛西林钠及阿奇霉素治疗小儿肺炎链球菌肺炎的临床疗效及其对免疫炎症因子的影响[J].世界中西医结合杂志,2021,16(6):1137-1140.[17]王卫中,田静,李艳微,等.美洛西林联合阿奇霉素治疗小儿肺炎链球菌肺炎疗效及影像学特征观察[J].河北医药,2017,39(19):2947-2949.[18]龚庆华,李桦,杨涛毅.美洛西林联合阿奇霉素治疗小儿肺炎链球菌肺炎的临床疗效分析[J].实用医院临床杂志,2017,14(2):98-100.[19]Nobuhisa I,Naoko K,Miki K,et al.Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients[J].PLoS One,2017,12(3):e0173635.[20]Zhou J,Jiang L,Zhang ZL,et al.Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants[J].Journal of Antimicrobial Chemotherapy,2022,77(8):2238-2244.

更新日期/Last Update: 1900-01-01